六味五灵片联合恩替卡韦治疗乙型肝炎肝硬化临床研究

Clinical efficacy of Liuweiwuling tablet combined with entecavir tablet on hepatitis cirrhosis

目的:观察六味五灵片联合恩替卡韦治疗乙型肝炎(CHB)肝硬化患者的临床疗效。方法:选择2010年6月到2012年6月沧州市传染病医院治疗的乙型肝炎肝硬化患者80例,随机分成治疗组42例和对照组38例。治疗组患者采用恩替卡韦联合六味五灵片治疗,对照组患者只用恩替卡韦。观察并比较治疗前和治疗24周、48周时两组患者临床表现、肝功能、肝纤维化指标和HBV DNA载量。结果:两组患者治疗前后肝功能比较,ALT、AST和TBil水平均显著下降(P<0.01),且治疗组患者治疗后的下降水平显著优于对照组(P<0.05),差异有统计学意义;两组患者治疗后肝纤维化指标,HA、PCIII、IV-C、和LN水平均较治疗前显著下降(P<0.01),且治疗组患者治疗后的下降水平显著优于对照组(P<0.05),差异有统计学意义;两组患者治疗24周、48周时HBV DNA转阴率均显著升高(P<0.01),但治疗组患者治疗后的升高水平显著优于对照组(P<0.05),差异均具有统计学意义;治疗组总有效率为92.8%,明显优于对照组的76.3%(P<0.05),差异有统计学意义。结论:六味五灵片与恩替卡韦联合运用可明显促进CHB肝硬化患者肝功能的恢复,改善临床症状,降低肝纤维化指标水平,且未见明显不良反应,患者耐受性好。

Objective： To explore the clinical efficacy of Liuweiwuling tablets combined with entecavir tablet on hepatitis cirrhosis. Methods： From June 2010 to June 2012, 80 cases of hepatitis B cirrhosis patients of Cangzhou infectious diseases hospital were randomly divided into two groups： The treatment group and the control group. The treatment group （42 cases） were given Liuweiwuling tablets combined with entecavir tablets, and the control group （38 cases） were only given entecavir tablets. Observe and compare the clinical manifestations , liver function , liver fibrosis index and HBV DNA load of the two groups before and after the treatment 24 weeks and 48 weeks. Results： The lever of the liver function indicators （AL.T, AST , and TBil） of the two groups decreased significantly after treatment compared before treatment （P 〈 0. 01 ） , and the decreased levels of the treatment group was significantly better than the control group （P 〈 0.05 ） . Secondly, the lever of the liver fibrosis indicates （ HA , PCⅢ,Ⅳ- C and LN） of the two groups decreased significantly after treatment compared before treatment （P 〈0.01 ） , and the decreased levels of the treatment group was significantly better than the control group （P 〈 0. 05 ） . Third, the HBV DNA negative rate of the tw6 groups after treatment 24 weeks and 48 weeks were significantly higher than before （ P 〈 0. 01 ）, and the increased levels of the treatment group was significantly higher than the control group （P 〈 0. 05 ） . Furthermore, the o- verall efficiency of the treatment group （ 92. 8% ） was significantly better than the control group （ 76. 3 % ） （P 〈0. 05 ） , and the difference was statistically significant. Conclusion： The combination therapy of Liuweiwuling tablet and entecavir can signifi- cantly promote the normalization and improve the clinical symptoms of patients with chronic hepatitis B , so the decIine in liver fibrosis indicators. What＇s more, there＇s no significant adverse reactions , and it has a good patient tolerance.